Bristol Myers Squibb (CELG-RI) Other Working Capital Changes (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Other Working Capital Changes of $1.6 billion for Q1 2026, up 54.49% year-over-year from $1.1 billion in Q1 2025, and up 253.18% quarter-over-quarter from -$1.1 billion in Q4 2025.
Bristol Myers Squibb (CELG-RI) Other Working Capital Changes (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Other Working Capital Changes data on file, last reported at $1.6 billion in Q1 2026.
- Other Working Capital Changes for Q1 2026 came in at $1.6 billion, up 54.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $106.0 million (up 161.27% YoY), and the FY2025 annual result was -$471.0 million, up 24.52% from the prior year.
- Other Working Capital Changes advanced to $1.6 billion in Q1 2026 per CELG-RI's latest filing, from -$1.1 billion in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $1.6 billion in Q1 2026 and troughed at -$1.1 billion in Q4 2025.
- A 5-year average of $106.9 million and a median of -$167.0 million in 2024 frame the typical range for Other Working Capital Changes.
- The sharpest annual moves came in 2022 and 2024: Other Working Capital Changes jumped 185.27% in 2022, then tumbled 383.05% in 2024.
- A 5-year view of Other Working Capital Changes shows it stood at -$700.0 million in 2022, then jumped by 59.57% to -$283.0 million in 2023, then tumbled by 156.18% to -$725.0 million in 2024, then sank by 47.31% to -$1.1 billion in 2025, then jumped by 253.18% to $1.6 billion in 2026.
- Business Quant data shows CELG-RI's Other Working Capital Changes at $1.6 billion in Q1 2026, -$1.1 billion in Q4 2025, and -$240.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.64 Bn |
| Mar 31, 2026 | 1.64 Bn |
| Dec 31, 2025 | -1.07 Bn |
| Dec 31, 2025 | -1.07 Bn |
| Sep 30, 2025 | -240.00 Mn |
| Sep 30, 2025 | -240.00 Mn |
| Jun 30, 2025 | -222.00 Mn |
| Jun 30, 2025 | -222.00 Mn |
| Mar 31, 2025 | 1.06 Bn |
| Mar 31, 2025 | 1.06 Bn |
| Dec 31, 2024 | -725.00 Mn |
| Dec 31, 2024 | -725.00 Mn |
| Sep 30, 2024 | -167.00 Mn |
| Sep 30, 2024 | -167.00 Mn |
| Jun 30, 2024 | -340.00 Mn |
| Jun 30, 2024 | -340.00 Mn |
| Mar 31, 2024 | 608.00 Mn |
| Mar 31, 2024 | 608.00 Mn |
| Dec 31, 2023 | -283.00 Mn |
| Dec 31, 2023 | -283.00 Mn |